Infectious Disease · Human Immunodeficiency Virus (HIV) Infection

Managing Advanced HIV and Immune Recovery

At a Glance

Advanced HIV means the immune system is severely weakened, usually shown by a CD4 count below 200 cells/mm³ or an AIDS-defining illness. Antiretroviral therapy can help rebuild immunity, while prophylaxis lowers infection risk and new or worsening symptoms require prompt medical assessment.

Hearing that your condition is classified as Advanced HIV (historically called AIDS) can be frightening, but it is important to remember that this is a clinical snapshot of your immune system today ^[1]. Advanced HIV is typically defined as having a CD4 count below 200 cells/mm³ (or CD4 percentage below 14%) or being diagnosed with an “AIDS-defining” illness ^[2]^[3]. If you have met the criteria for AIDS, that diagnosis remains part of your medical history, but it is not a permanent prediction of poor health. With modern treatment, many people who reach this stage see their immune systems recover significantly ^[4].

What are Opportunistic Infections (OIs)?

When your CD4 count is low, your immune system is spread thin. This allows Opportunistic Infections (OIs)—germs that a healthy body normally keeps in check—to take advantage of the situation and cause illness ^[5].

Common OIs that doctors watch for include:

Pneumocystis jirovecii pneumonia (PJP or PCP): A fungal infection of the lungs that causes a dry cough, fever, and shortness of breath ^[6].
Toxoplasmosis: A parasite that can cause brain lesions, leading to headaches, confusion, or seizures ^[7].
Tuberculosis (TB): A bacterial infection that often attacks the lungs but can spread throughout the body ^[8].
Cryptococcosis: A fungus that can lead to meningitis (inflammation of the brain and spinal cord) ^[9].

The Role of Prophylaxis

To protect you while your immune system recovers, your doctor may prescribe prophylaxis—preventive medicine designed to stop OIs before they start.

The preferred prophylaxis is Trimethoprim-sulfamethoxazole (TMP-SMX), often known by the brand name Bactrim. It is the preferred first-line agent for preventing PJP and, depending on your Toxoplasma IgG status and CD4 level, can also provide protection against toxoplasmosis ^[10]^[7]. If you have an allergy to sulfa, your clinician can provide alternatives. If your CD4 count is very low, guidelines also support cryptococcal-antigen screening or MAC prevention.

You should not stop taking these medications on your own. Guidelines generally allow you to stop prophylaxis once your CD4 count stays above 200 cells/mm³ for at least three months on Antiretroviral Therapy (ART) (or sometimes earlier based on viral suppression), but stopping thresholds are individualized ^[11]^[12].

Understanding IRIS and Urgent Symptoms

As you begin ART and your viral load drops, your immune system begins to “rebuild” itself. While this is the goal of treatment, it can sometimes cause a temporary complication called Immune Reconstitution Inflammatory Syndrome (IRIS) ^[13].

IRIS occurs when your recovering immune system suddenly recognizes a hidden infection and launches an aggressive, inflammatory attack against it ^[14]. This can cause your symptoms to temporarily worsen or new symptoms to appear shortly after starting treatment ^[15].

When it happens: Usually within the first few weeks to six months of starting ART ^[15].
Who is at risk: It is most common in people who started treatment with a very low CD4 count (below 50 or 100) or who had a high amount of virus in their blood ^[16].
What to look for: Fever, newly swollen lymph nodes, or a rapidly worsening of symptoms ^[15].

Worsening fever, shortness of breath, severe headache, confusion, neck stiffness, vision changes, or rapidly enlarging lymph nodes after starting ART need prompt medical assessment. They can represent IRIS, but they can also indicate an untreated OI, a drug reaction, or treatment failure. Contact your HIV team urgently if these occur. ART is usually continued, but diagnosis and timing require clinical assessment, particularly with cryptococcal or TB meningitis ^[16]^[17]^[18].

Common questions in this guide

What does an advanced HIV or AIDS diagnosis mean?

Advanced HIV usually means a CD4 count below 200 cells/mm³, a CD4 percentage below 14%, or an AIDS-defining illness. An AIDS diagnosis remains part of your medical history, but it does not permanently predict poor health because treatment can help the immune system recover.

Which infections are more likely when HIV has weakened my immune system?

Low CD4 counts can allow opportunistic infections to cause illness. Examples include Pneumocystis jirovecii pneumonia, toxoplasmosis, tuberculosis, and cryptococcosis, which may affect the lungs, brain, or other parts of the body.

Why might my HIV clinician prescribe Bactrim?

Bactrim, also called trimethoprim-sulfamethoxazole, is the preferred preventive medicine for Pneumocystis jirovecii pneumonia. Depending on your CD4 count and Toxoplasma antibody status, it may also help prevent toxoplasmosis. People with sulfa allergies may need a different option.

When can I stop medicine that prevents opportunistic infections?

Do not stop preventive medicine on your own. Clinicians generally consider stopping after the CD4 count has remained above 200 cells/mm³ for at least three months while you are taking antiretroviral therapy, although viral suppression and other factors may change the plan.

What is IRIS after starting HIV treatment?

Immune Reconstitution Inflammatory Syndrome, or IRIS, is an inflammatory reaction that can occur as the immune system begins to recover after antiretroviral therapy starts. It often appears during the first few weeks to six months and may cause fever, swollen lymph nodes, or worsening symptoms, especially when the starting CD4 count is very low or the viral load is high.

Which symptoms after starting ART need urgent medical attention?

Contact your HIV care team promptly for worsening fever, shortness of breath, severe headache, confusion, neck stiffness, vision changes, or rapidly enlarging lymph nodes. These symptoms may be caused by IRIS, an untreated infection, a medication reaction, or treatment failure, so clinical assessment is important.

Curated prompts to bring to your next appointment.

1.What is my current CD4 count, and do my laboratory results meet the definition for 'advanced HIV' or 'AIDS'?
2.Based on my labs and Toxoplasma IgG status, do I need to start taking Bactrim to prevent PJP or other infections?
3.Are there specific signs of Immune Reconstitution Inflammatory Syndrome (IRIS) I should watch for during my first few months on ART?
4.If I am allergic to sulfa drugs, what alternative prophylaxis options exist for me?
5.At what CD4 count and viral load level will it be safe for me to stop taking preventive medications under your supervision?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Key takeaways

Advanced HIV generally means a CD4 count below 200 cells/mm³, a CD4 percentage below 14%, or an AIDS-defining illness.
A past AIDS diagnosis remains in medical history but does not determine future health; antiretroviral therapy can allow significant immune recovery.
TMP-SMX, commonly known as Bactrim, is preferred prophylaxis for Pneumocystis jirovecii pneumonia and may also prevent toxoplasmosis depending on Toxoplasma antibody status and CD4 level.
IRIS can cause new or worsening symptoms after antiretroviral therapy begins, particularly when the starting CD4 count is very low or the viral load is high.
Preventive medicines should be stopped only with clinical supervision, often after the CD4 count stays above 200 cells/mm³ for at least three months on antiretroviral therapy.

References (18)

1
Modelling the impact of CD4 testing on mortality from TB and cryptococcal meningitis among patients with advanced HIV disease in nine countries.
Oboho IK, Paulin H, Corcoran C, et al.
Journal of the International AIDS Society 2023; (26(3)):e26070 doi:10.1002/jia2.26070.
PMID: 36880429
2
Mortality and immunovirological outcomes in patients with advanced HIV disease on their first antiretroviral treatment: differential impact of antiretroviral regimens.
Burgos J, Moreno-Fornés S, Reyes-Urueña J, et al.
The Journal of antimicrobial chemotherapy 2022; (78(1)):108-116 doi:10.1093/jac/dkac361.
PMID: 36308326
3
Late presentations and missed opportunities among newly diagnosed HIV patients presenting to a specialty clinic in Lebanon.
Mahmoud M, Ballouz T, Lahoud C, et al.
Scientific reports 2024; (14(1)):8296 doi:10.1038/s41598-024-55277-1.
PMID: 38594292
4
The benefit of immediate compared with deferred antiretroviral therapy on CD4+ cell count recovery in early HIV infection.
Sharma S, Schlusser KE, de la Torre P, et al.
AIDS (London, England) 2019; (33(8)):1335-1344 doi:10.1097/QAD.0000000000002219.
PMID: 31157663
5
Pneumocystis Pneumonia-Is it Still a Threat Among People With Human Immunodeficiency Virus (HIV)? A Danish HIV Cohort Study.
Møller AK, Schnoor SB, Petersen I, et al.
Open forum infectious diseases 2025; (12(6)):ofaf289 doi:10.1093/ofid/ofaf289.
PMID: 40463830
6
Integrase strand transfer inhibitor treatment does not increase the incidence of immune reconstitution inflammatory syndrome in HIV-infected Koreans.
Kim J, Nam HJ, Kang SJ, et al.
HIV medicine 2021; (22(8)):705-714 doi:10.1111/hiv.13117.
PMID: 34046975
7
Central nervous system infection with Toxoplasma gondii.
Marra CM
Handbook of clinical neurology 2018; (152()):117-122 doi:10.1016/B978-0-444-63849-6.00009-8.
PMID: 29604970
8
HIV-Associated TB Syndemic: A Growing Clinical Challenge Worldwide.
Montales MT, Chaudhury A, Beebe A, et al.
Frontiers in public health 2015; (3()):281 doi:10.3389/fpubh.2015.00281.
PMID: 26779470
9
The Diagnostic Laboratory Hub: A New Health Care System Reveals the Incidence and Mortality of Tuberculosis, Histoplasmosis, and Cryptococcosis of PWH in Guatemala.
Samayoa B, Aguirre L, Bonilla O, et al.
Open forum infectious diseases 2020; (7(1)):ofz534 doi:10.1093/ofid/ofz534.
PMID: 31915715
10
Comparative efficacy and safety of Pneumocystis jirovecii pneumonia prophylaxis regimens for people living with HIV: a systematic review and network meta-analysis of randomized controlled trials.
Prosty C, Katergi K, Sorin M, et al.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2024; (30(7)):866-876 doi:10.1016/j.cmi.2024.03.037.
PMID: 38583518
11
No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µL.
Atkinson A, Miro JM, Mocroft A, et al.
Journal of the International AIDS Society 2021; (24(6)):e25726 doi:10.1002/jia2.25726.
PMID: 34118121
12
Discontinuing Pneumocystis jirovecii Pneumonia Prophylaxis in HIV-Infected Patients With a CD4 Cell Count <200 cells/mm3.
Sidhu VK, Foisy MM, Hughes CA
The Annals of pharmacotherapy 2015; (49(12)):1343-8 doi:10.1177/1060028015605113.
PMID: 26358129
13
Opportunistic infections and immune reconstitution inflammatory syndrome in HIV-1-infected adults in the combined antiretroviral therapy era: a comprehensive review.
Manzardo C, Guardo AC, Letang E, et al.
Expert review of anti-infective therapy 2015; (13(6)):751-67 doi:10.1586/14787210.2015.1029917.
PMID: 25860288
14
Tuberculosis-immune reconstitution inflammatory syndrome.
Lanzafame M, Vento S
Journal of clinical tuberculosis and other mycobacterial diseases 2016; (3()):6-9 doi:10.1016/j.jctube.2016.03.002.
PMID: 31723680
15
Immune reconstitution inflammatory syndrome in HIV-infected patients.
Walker NF, Scriven J, Meintjes G, Wilkinson RJ
HIV/AIDS (Auckland, N.Z.) 2015; (7()):49-64 doi:10.2147/HIV.S42328.
PMID: 25709503
16
The tuberculosis-associated immune reconstitution inflammatory syndrome: recent advances in clinical and pathogenesis research.
Walker NF, Stek C, Wasserman S, et al.
Current opinion in HIV and AIDS 2018; (13(6)):512-521 doi:10.1097/COH.0000000000000502.
PMID: 30124473
17
Immune Reconstitution Inflammatory Syndrome Associated Kaposi Sarcoma.
Poizot-Martin I, Brégigeon S, Palich R, et al.
Cancers 2022; (14(4)) doi:10.3390/cancers14040986.
PMID: 35205734
18
Management of active tuberculosis in adults with HIV.
Meintjes G, Brust JCM, Nuttall J, Maartens G
The lancet. HIV 2019; (6(7)):e463-e474 doi:10.1016/S2352-3018(19)30154-7.
PMID: 31272663

This page explains advanced HIV, opportunistic infection prevention, and IRIS for informational purposes only; it does not replace medical advice. Contact your HIV care team for personal guidance, especially if symptoms worsen after starting ART.

Get notified when new evidence is published on HIV infectious disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents